Pfizer, Astellas, and Actinium are involved in a competitive landscape for prostate cancer drugs, including Xtandi and ATNM-400.

1 report, 0 independent Updated Jul 3

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

SpeculativeNo independent reporting found

Who's involved

What this event is mainly about

Pfizer Astellas (South Korea)Actinium Pharmaceuticals (United States)

Keep exploring

Part of

Major pharmaceutical companies are driving innovation and competing in the non-metastatic prostate cancer market. All 2 developments

The entities involved

Pfizer
American multinational pharmaceutical and biotechnology corporation
- Dave Long trained at Fort Knox after graduating from Boardman High School and later worked for Pfizer.Mon 05:00
- MarketBeat's screener has identified a list of dividend stocks.Sun 22:22
Astellas (South Korea)
company in Seoul, South Korea

Nothing else this week.
Actinium Pharmaceuticals (United States)
company in New York, United States

Nothing else this week.

Coverage

Newest first; wire copies grouped

Jul 3Unknown outlet